title: Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".
authors.affiliation: 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Division of Translational Therapeutics, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada.
authors.forename: B C
authors.initials: BC
authors.lastname: Carleton
authors.affiliation: 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Division of Translational Therapeutics, Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada [3] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [4] Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: C J
authors.initials: CJ
authors.lastname: Ross
authors.affiliation: 1] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [2] Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: A P
authors.initials: AP
authors.lastname: Bhavsar
authors.affiliation: 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [3] Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: J W
authors.initials: JW
authors.lastname: Lee
authors.affiliation: Department of Pediatrics, Amalia Children's Hospital, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: Visscher
authors.affiliation: 1] Child and Family Research Institute, Vancouver, British Columbia, Canada [2] Pharmaceutical Outcomes Programme, BC Children's Hospital, Vancouver, British Columbia, Canada [3] Division of Pediatric Hematology/Oncology/Bone Marrow Transplant, Department of Pediatrics, BC Children's Hospital, Vancouver, British Columbia, Canada.
authors.forename: S R
authors.initials: SR
authors.lastname: Rassekh
authors.affiliation: Centre for Molecular Medicine and Therapeutics; Department of Medical Genetics, The University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: M R
authors.initials: MR
authors.lastname: Hayden
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D002394:Catechol O-Methyltransferase / Q000235:genetics*; D002945:Cisplatin / Q000633:toxicity*; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008780:Methyltransferases / Q000235:genetics*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D002394:Catechol O-Methyltransferase; D002945:Cisplatin; D008780:Methyltransferases; D027425:ATP-Binding Cassette, Sub-Family C Proteins